Prof. Didier Hans, PhD, MBA co-founded Med-Imaps SA in 2006 and became CEO of Medimaps Group in 2012. He currently drives the company’s global strategy, orientation and business objectives, and oversees its Quality Management framework and policies.He holds a PhD in Medical Physics and an Executive MBA from HEC Geneva. https://www.medimapsgroup.com/team/didier-hans/
One of Medimaps Group's products, TBS iNsight™ (Osteo), is an advanced imaging software application for bone densitometers (DXA). It provides a way to better predict a patient’s risk for bone fracture, to fine-tune therapy decisions, and to improve patient management.
TBS iNsight™ is a Medical Device that is CE 2797 marked & has been cleared to be sold in the US.
https://www.medimapsgroup.com/tbs-osteo/
I recently had the opportunity to ask Prof. Hans a question by email. He graciously answered.
My question:
Will a TBS score be affected by the bone strontium effect, as the BMD by DXA scan is?
His answer, paraphrased and confirmed:
In our study of TBS and strontium ranelate, TBS was less affected by the larger atomic number of strontium than the BMD was affected. So, the study showed that strontium improved bone microarchitecture.
4 comments:
Excellent news!
To Anonymous,
Excellent news, indeed!
Just found this specific topic link from Inspire.com - have to say that it gives me a measure of satisfaction when my Dr told me to only use something that has been proven to help bones
To: Anonymous of 9/13/2025
Prof. Didier Hans made me feel very happy when he said that strontium improved bone microarchitecture as shown by TBS, which is less affected by strontium than the BMD is affected.
Post a Comment